Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 15/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21274066 | 0.89 | PIK3CD (0.40) | NR1H2NR1H3DRD2MLYCDJAK2 | |
| SCHEMBL21274063 | 0.89 | PIK3CD (0.40) | NR1H2NR1H3DRD2MLYCDJAK2 | |
| SCHEMBL21274365 | 0.84 | DRD2 (0.43) | NR1H2NR1H3DRD2MLYCDJAK2 | |
| SCHEMBL21274364 | 0.84 | DRD2 (0.43) | NR1H2NR1H3DRD2MLYCDJAK2 | |
| SCHEMBL21274383 | 0.79 | GPR119 (0.40) | MLYCDJAK2JAK3PTK2 | |
| SCHEMBL21274380 | 0.79 | GPR119 (0.40) | MLYCDJAK2JAK3PTK2 | |
| SCHEMBL21268721 | 0.79 | GPR119 (0.39) | MLYCDJAK2JAK3PTK2 | |
| SCHEMBL21268723 | 0.79 | GPR119 (0.39) | MLYCDJAK2JAK3PTK2 | |
| SCHEMBL21274333 | 0.77 | GPR119 (0.44) | — | |
| SCHEMBL21274332 | 0.77 | GPR119 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | NR1H2 245/4885NR1H3 379/4885DRD2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.